“Safety and Adverse Events of Special Interest in 825 Adults With Atopic Dermatitis Receiving Up to 12 Months of Tralokinumab Treatment in a Real-World Setting”. SKIN The Journal of Cutaneous Medicine 10, no. 2 (March 10, 2026): s730. Accessed May 1, 2026. https://skin.dermsquared.com/skin/article/view/4039.